Compare Davita Inc (DVA) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Centrus Energy Corp — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Centrus Energy Corp trades at $144.89 (market cap $2.91B). The key difference: Davita Inc is far larger — about 3.9× Centrus Energy Corp's market cap, and Davita Inc is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Centrus Energy Corp for 29 Days on average.
| DVA | LEU | |
|---|---|---|
Market Cap | $11.29B | $2.91B |
Volume | 582,204 | 903,777 |
Sector | Health | Energy |
52-Week High | $240.96 | $436.00 |
52-Week Low | $103.87 | $138.18 |
Typical Hold Time | 113 Days | 29 Days |
Enterprise Value | $24.01B | $2.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Centrus Energy (LEU) trades at $147.14, down 4.38% on the day, with a neutral technical signal. The company reported Q2 2026 EPS of $0.77, beating estimates, but faces declining profitability margins into 2026. Recent news highlights its strategic position as a supplier of High-Assay Low-Enriched Uranium (HALEU), benefiting from U.S. nuclear energy growth and partnerships, though execution risks remain high.
Outlook is mixed: strong analyst consensus price target of $218.10 implies significant upside, supported by nuclear sector tailwinds and new contracts. However, high valuation multiples (P/E 77.85), volatile cash flows, and margin compression pose risks. Investors should weigh growth potential against execution challenges in a capital-intensive industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
